不可逆FLT3抑制剂FF-10101治疗复发或难治性急性髓系白血病的1期研究
这项1期剂量递增研究评估了口服FF-10101在复发和/或难治性急性髓系白血病患者中的安全性和疗效,54例受试者接受每日10至225mg或每日两次50至100mg给药。剂量限制性毒性为腹泻和QT间期延长,推荐的2期剂量为每日两次75mg。在40例可评估疗效的受试者中,复合完全缓解率为10%,总缓解率(包括部分缓解)为12.5%,包括既往接受吉瑞替尼后进展的患者。
要点
- FF-10101剂量限制性毒性为腹泻和QT间期延长。
- 推荐的2期剂量为每日两次75mg。
- 40例可评估者中复合完全缓解率10%、总缓解率12.5%。
核心结论
- FF-10101可能代表FLT3突变急性髓系白血病治疗的下一代进步。
研究设计与样本
- 1期剂量递增研究,纳入复发和/或难治性急性髓系白血病患者54例,口服FF-10101剂量范围为每日10至225mg及每日两次50至100mg。
主要发现
- 剂量限制性毒性为腹泻和QT间期延长。
- 54例受试者中56%既往暴露于FLT3抑制剂。
- 40例可评估疗效的受试者中,复合完全缓解率为10%,总缓解率(包括部分缓解)为12.5%,包括既往接受吉瑞替尼后进展的患者。
- 推荐的2期剂量为每日两次75mg。
关键数值与推荐
- 复合完全缓解率为10%(40例可评估受试者中)。
- 总缓解率(包括部分缓解)为12.5%(40例可评估受试者中)。
- 推荐的2期剂量为每日两次75mg。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination therapies. FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling. It is effective against most FLT3 activating mutations, and, unlike other inhibitors, is minimally vulnerable to resistance induced by FLT3 ligand. We conducted a phase 1 dose escalation study of oral FF-10101 in patients with relapsed and/or refractory AML, the majority of whom harbored FLT3-activating mutations and/or had prior exposure to FLT3 inhibitors. Fifty-four participants enrolled in cohorts receiving doses ranging from 10 to 225 mg per day and 50 to 100 mg twice daily (BID). The dose limiting toxicities were diarrhea and QT prolongation. Among 40 response-evaluable participants, the composite complete response rate was 10%, and the overall response rate (including partial responses) was 12.5%, including patients who had progressed on gilteritinib. Overall, 56% of participants had prior exposure to FLT3 inhibitors. The recommended phase 2 dose was 75 mg BID. FF-10101 potentially represents a next-generation advance in the management of FLT3-mutated AML. This trial was registered at www.ClinicalTrials.gov as #NCT03194685.
引用
- Levis M, Perl A, Schiller G, et al. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood Adv. 2024. PMID: 38502195. doi:10.1182/bloodadvances.2023010619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。